Insight Molecular Diagnostics Inc (IMDX)

$2.40 -0.05 (-2.04%)
Market Cap 70.12M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 13,600
Avg Vol 86,410
Day's Range N/A - N/A
Shares Out 28.62M
Stochastic %K 14%
Beta 1.05
Analysts Sell
Price Target $5.42

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
RUNNINWILD
RUNNINWILD Aug. 12 at 4:30 PM
$IMDX doing a little pecking DCA today
0 · Reply
prismmarketview
prismmarketview Aug. 12 at 2:49 PM
Nasdaq: $IMDX Insight Molecular Diagnostics @iMDxInc posted Q2 revenue of $518K and reiterated plans to submit its GraftAssureDx transplant monitoring assay to the FDA by year-end, targeting a mid-2026 launch. Clinical trials are enrolling top transplant centers, and new data highlights the potential for broader dd-cfDNA applications across multiple organ types https://prismmarketview.com/insight-molecular-diagnostics-reports-q2-results-maintains-timeline-for-graftassuredx-fda-submission/
0 · Reply
jackedmund99
jackedmund99 Aug. 11 at 9:21 PM
$IMDX after hour trades are bullshit nothing crap
0 · Reply
jackedmund99
jackedmund99 Aug. 11 at 9:19 PM
$IMDX big change in the manner of presentation - the company is forecasting a serious change in its approach and appearance looking to sales taking off as acceptance is processed
0 · Reply
JohnPDaly
JohnPDaly Aug. 11 at 8:08 PM
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch – Insight Molecular Diagnostics Inc.$IMDX https://investors.imdxinc.com/news-releases/2025/08-11-2025-210552669
0 · Reply
JohnPDaly
JohnPDaly Aug. 4 at 8:26 PM
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference $IMDX https://finance.yahoo.com/news/imdx-release-second-quarter-2025-200500359.html
0 · Reply
jackedmund99
jackedmund99 Jul. 31 at 10:16 PM
$IMDX finally updated - now the conversation can continue stock isn’t getting any respect big news out continue to wait till the world wakes up
1 · Reply
jackedmund99
jackedmund99 Jul. 31 at 6:52 PM
$IMDX when is this site going to Update the symbol! $IMDX
0 · Reply
JoseGilberto109
JoseGilberto109 Jul. 31 at 2:36 AM
$IMDX Up nice
0 · Reply
jackedmund99
jackedmund99 Jul. 30 at 8:35 PM
$IMDX huge news out
0 · Reply
Latest News on IMDX
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 11, 2025, 4:05 PM EDT - 3 days ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Aug 4, 2025, 4:05 PM EDT - 10 days ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 30, 2025, 4:05 PM EDT - 15 days ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jul 28, 2025, 4:05 PM EDT - 17 days ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 23, 2025, 4:05 PM EDT - 7 weeks ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Jun 17, 2025, 7:00 AM EDT - 2 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 3 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 3 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 3 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 3 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 3 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Apr 29, 2025, 8:30 AM EDT - 3 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 5 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025, 4:05 PM EDT - 5 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025, 8:30 AM EST - 6 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025, 8:30 AM EST - 7 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 7 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 9 months ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024, 4:45 PM EST - 10 months ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024, 4:15 PM EDT - 10 months ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Oncocyte Announces Reduction in Force

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Oncocyte Completes Razor Genomics Transaction

Feb 22, 2023, 8:00 AM EST - 2 years ago

Oncocyte Completes Razor Genomics Transaction

Oncocyte cuts 40% of staff

Dec 16, 2022, 8:19 AM EST - 2 years ago

Oncocyte cuts 40% of staff

Oncocyte Announces Initiatives to Focus Corporate Strategy

Dec 16, 2022, 8:00 AM EST - 2 years ago

Oncocyte Announces Initiatives to Focus Corporate Strategy

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Nov 30, 2022, 6:05 PM EST - 2 years ago

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Oncocyte Announces Executive Leadership Changes

Nov 30, 2022, 6:00 PM EST - 2 years ago

Oncocyte Announces Executive Leadership Changes

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 9:50 PM EST - 3 years ago

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

RUNNINWILD
RUNNINWILD Aug. 12 at 4:30 PM
$IMDX doing a little pecking DCA today
0 · Reply
prismmarketview
prismmarketview Aug. 12 at 2:49 PM
Nasdaq: $IMDX Insight Molecular Diagnostics @iMDxInc posted Q2 revenue of $518K and reiterated plans to submit its GraftAssureDx transplant monitoring assay to the FDA by year-end, targeting a mid-2026 launch. Clinical trials are enrolling top transplant centers, and new data highlights the potential for broader dd-cfDNA applications across multiple organ types https://prismmarketview.com/insight-molecular-diagnostics-reports-q2-results-maintains-timeline-for-graftassuredx-fda-submission/
0 · Reply
jackedmund99
jackedmund99 Aug. 11 at 9:21 PM
$IMDX after hour trades are bullshit nothing crap
0 · Reply
jackedmund99
jackedmund99 Aug. 11 at 9:19 PM
$IMDX big change in the manner of presentation - the company is forecasting a serious change in its approach and appearance looking to sales taking off as acceptance is processed
0 · Reply
JohnPDaly
JohnPDaly Aug. 11 at 8:08 PM
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch – Insight Molecular Diagnostics Inc.$IMDX https://investors.imdxinc.com/news-releases/2025/08-11-2025-210552669
0 · Reply
JohnPDaly
JohnPDaly Aug. 4 at 8:26 PM
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference $IMDX https://finance.yahoo.com/news/imdx-release-second-quarter-2025-200500359.html
0 · Reply
jackedmund99
jackedmund99 Jul. 31 at 10:16 PM
$IMDX finally updated - now the conversation can continue stock isn’t getting any respect big news out continue to wait till the world wakes up
1 · Reply
jackedmund99
jackedmund99 Jul. 31 at 6:52 PM
$IMDX when is this site going to Update the symbol! $IMDX
0 · Reply
JoseGilberto109
JoseGilberto109 Jul. 31 at 2:36 AM
$IMDX Up nice
0 · Reply
jackedmund99
jackedmund99 Jul. 30 at 8:35 PM
$IMDX huge news out
0 · Reply
JohnPDaly
JohnPDaly Jul. 30 at 8:17 PM
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/07-30-2025-210715782
0 · Reply
jackedmund99
jackedmund99 Jul. 28 at 11:52 PM
$IMDX $IMDX news out .- event on Aug 15 to discuss in house DD-CFDNA testing for Kidney Transplant patients featuring Dr Anthony Langone of Vanderbilt University and provide overview of GraftAssure family of assays
0 · Reply
JohnPDaly
JohnPDaly Jul. 28 at 8:12 PM
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/07-28-2025-210551511
0 · Reply
jackedmund99
jackedmund99 Jul. 14 at 5:51 PM
$IMDX get the new ticker $IMDX
0 · Reply
RUNNINWILD
RUNNINWILD Jul. 10 at 5:30 PM
$IMDX anyone know when options will start to trade under the new ticker
0 · Reply
jackedmund99
jackedmund99 Jul. 8 at 7:28 PM
$IMDX $NTRA has 21 billion market cap
1 · Reply
jackedmund99
jackedmund99 Jul. 7 at 5:47 PM
$IMDX when will you clowns update this to $IMDX ?
0 · Reply
JoseGilberto109
JoseGilberto109 Jul. 5 at 1:06 AM
$IMDX Why did it dip ?
0 · Reply
RUNNINWILD
RUNNINWILD Jul. 2 at 3:07 PM
$IMDX starter in @ 3.05
0 · Reply
jackedmund99
jackedmund99 Jul. 1 at 10:55 PM
$IMDX up date this $IMDX
0 · Reply
jackedmund99
jackedmund99 Jun. 23 at 8:35 PM
$IMDX news out showing head to head equivalence with current available test kits- “digital PCR showed improved analytical sensitivity suggesting advantages in detecting dd- cfDNA in low quantities” said chief science officer Dr. Ekkehard Schuetz
0 · Reply
JohnPDaly
JohnPDaly Jun. 23 at 8:34 PM
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/06-23-2025-210517643
0 · Reply